Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer, Perosphere Anticoagulant Antidotes Advance At AHA

Executive Summary

At a time when demand for anticoagulant antidotes is high, the 2013 AHA meeting featured the first human data for two new reversal agents from Boehringer Ingelheim and Perosphere. Perosphere will be pursuing “breakthrough therapy” status with FDA for its intravenous small molecule candidate PER977.

You may also be interested in...



Daiichi’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto

Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.

Answering The Call For Antidotes

Bad publicity about bleeding events spells headaches for drug developers, but also an opportunity for companies that can come up with antidotes to reverse anticoagulation effects.

The Antidote To Competition: Portola’s Rivals Fund Study On Class-Wide Anticoagulant Antidote

Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel